Intensive pharmacokinetics of the nelfinavir-rifabutin interaction in patients with HIV-related tuberculosis treated with a rifabutin-based regimen

Trial Profile

Intensive pharmacokinetics of the nelfinavir-rifabutin interaction in patients with HIV-related tuberculosis treated with a rifabutin-based regimen

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Efavirenz (Primary) ; Rifabutin (Primary) ; Isoniazid; Nucleoside reverse transcriptase inhibitors
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top